finance

Barclays downgrades Reata Pharma to 'equalweight' with a price target of $172.00




Barclays downgrades Reata Pharma to 'equalweight' with a price target of $172.00



READ SOURCE

Readers Also Like:  Martin Lewis’ MSE reveals how parents left out of pocket over delayed child benefit payments can claim

This website uses cookies. By continuing to use this site, you accept our use of cookies.